Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cellerant Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cellerant Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Cellerant Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cellerant Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cellerant Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cellerant Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cellerant Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Cellerant Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cellerant Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cellerant Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cellerant Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellerant Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cellerant Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Cellerant Therapeutics, Inc. Snapshot 4 Cellerant Therapeutics, Inc. Overview 4 Key Information 4 Key Facts 4 Cellerant Therapeutics, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Cellerant Therapeutics, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Cellerant Therapeutics, Inc. - Pipeline Products Glance 9 Cellerant Therapeutics, Inc. - Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 Cellerant Therapeutics, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 Cellerant Therapeutics, Inc. - Drug Profiles 12 romyelocel-L 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Antibody to Target Cancer Stem Cell for Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 CLT-009 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Cellerant Therapeutics, Inc. - Pipeline Analysis 15 Cellerant Therapeutics, Inc. - Pipeline Products by Route of Administration 15 Cellerant Therapeutics, Inc. - Pipeline Products by Molecule Type 16 Cellerant Therapeutics, Inc. - Recent Pipeline Updates 17 Cellerant Therapeutics, Inc. - Dormant Projects 19 Cellerant Therapeutics, Inc. - Locations And Subsidiaries 20 Head Office 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 22 Disclaimer 22
List of Tables Cellerant Therapeutics, Inc., Key Information 4 Cellerant Therapeutics, Inc., Key Facts 4 Cellerant Therapeutics, Inc. - Pipeline by Indication, 2014 6 Cellerant Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7 Cellerant Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8 Cellerant Therapeutics, Inc. - Phase I, 2014 9 Cellerant Therapeutics, Inc. - Preclinical, 2014 10 Cellerant Therapeutics, Inc. - Discovery, 2014 11 Cellerant Therapeutics, Inc. - Pipeline by Route of Administration, 2014 15 Cellerant Therapeutics, Inc. - Pipeline by Molecule Type, 2014 16 Cellerant Therapeutics, Inc. - Recent Pipeline Updates, 2014 17 Cellerant Therapeutics, Inc. - Dormant Developmental Projects,2014 19
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.